EILEEN STARBRANCH: Open Payments
NPI 1982671590 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,312 in 12 payments from 7 companies in 2025. Trend: 2023 $1,145 · 2024 $1,480 · 2025 $1,312
Food & beverage: $1,312
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $328 |
| Otsuka America Pharmaceutical, Inc. | 2 | $251 |
| Luye Pharma (USA) Ltd. | 2 | $215 |
| E.R. Squibb & Sons, L.L.C. | 2 | $200 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $109 |
| Noven Therapeutics, LLC | 1 | $107 |
| Axsome Therapeutics, Inc. | 1 | $101 |
Products named: UZEDY, ERZOFRI EXTENDED-RELEASE, COBENFY, ABILIFY MAINTENA, ABILIFY ASIMTUFII, CAPLYTA, Xelstrym, Auvelity.
Industry payments across TX — which companies pay providers there.
